Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds

Biktarvy Settlement Totals $1.25bn Up Front, 3% US Bictegravir Royalty

The company said in its fourth quarter earnings report that it would not seek accelerated approval for the drug, while it also settled an HIV drug-related intellectual property lawsuit with GSK/ViiV.

Stopping the domino effect concept
Gilead announced Q4 and full year 2021 earnings on 1 February • Source: Alamy

Gilead Sciences, Inc. is calling off its effort to pursue accelerated approval of magrolimab in myelodysplastic syndrome (MDS), while the US Food and Drug Administration has placed partial clinical holds on additional Phase II trials of the drug, in multiple myeloma and diffuse large B-cell lymphoma (DLBCL), the company said in its fourth quarter earnings report.

Gilead also reached a settlement with GlaxoSmithKline plc and ViiV Healthcare regarding the HIV drug Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide),...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.